Discovery VIRUS COVID-19 Registry

A global COVID-19 registry that tracks ICU and hospital care patterns in near real-time

visual bubble
visual bubble
visual bubble
visual bubble
Viral Infection and Respiratory Illness Universal Study (VIRUS) is a prospective, cross-sectional, observational study and registry of all eligible adult and pediatric patients who are admitted to a hospital. There is no intervention or patient interaction. Only de-identified data is used for analysis.  ClinicalTrials.gov Identifier: NCT04323787
 


For individuals whose site is IRB approved: please join the SCCM Connect Discovery Group! ​Access includes a listserve of all participating sites, registry resources and updates of the VIRUS Registry Project.
 
 

STOP-VIRUS ICU Learning Collaborative

Adult ICUs participating in the VIRUS Registry with at least 3-6 months of data and are located within the United States or its Territories, are invited to apply for a new SCCM collaborative being launched in February 2021. The collaborative, which will be open to twenty sites, is entitled STOP-VIRUS (Structured Team-based Optimal Patient-centered care for virus covid-19). There is no fee to participate. Applications are being accepted through mid-April.

Learn More

VIRUS COVID-19 Registry Enrollment 


Please check whether your site is already enrolled as a VIRUS participating site before enrolling.

Check the VIRUS Participation List

Complete the Intake Form to Participate 

VIRUS FAQs


Inclusion criteria:  

  1. COVID-19 PCR (or other SARS-CoV-2) test positive (within 14 days)
  2. COVID-19 PCR pending 
  3. COVID-19 high clinical suspicion 

Primary aims: 

  • Create a real-time COVID-19 registry of current intensive care unit and hospital care patterns to allow evaluation of safety and observational effectiveness of COVID-19 practices 
  • Determine practice variations across hospitals 

Hypothesis

The registry will be essential for near-real-time observational comparative effectiveness studies to determine effective treatment strategies and/or provide meaningful hypotheses for clinical trials. 

Institutional Review Board: Waiver of Consent

A waiver of informed consent for data collection is being requested for this study from participating sites. No patients will be contacted, but clinicians participating in the study will be surveyed for feedback and satisfaction. For any questions, contact Vishakha Kumar.

Project Managers:

  • Karen Boman (Society of Critical Care Medicine)

  • Vikas Bansal, MBBS, MPH (Mayo Clinic)

visual bubble
visual bubble
visual bubble
visual bubble
visual bubble

VIRUS Investigators 

Discovery, the Critical Care Research Network, is leading the efforts for this global COVID-19 registry. 
Rahul Kashyap, MBBS, MBA
VIRUS Principal Investigator
Rahul Kashyap, MBBS, MBA

Co-Principal Investigators
Allen J. Walkey, MD, MSc, Boston University 
Vishakha Kumar, MD, MBA, Discovery Network, Society of Critical Care Medicine 

VIRUS Ancillary Studies

Ancillary study proposals may be submitted for a subset of de-identified data for research purposes by investigators of participating sites in the VIRUS study. The proposals are submitted via an online submission portal. Once submitted, the proposal will be received by Discovery VIRUS Publication Review Workgroup & Discovery Steering Committee for approval amd feedback.  
Datasets may be made available to outside groups (non-participating sites/investigators) after the initial publication of the data by VIRUS principal investigators. A DUA will need to be in place for this type of request.
 
The Discovery VIRUS Publication Review Workgroup will define the approvals via a transparent feedback mechanism to the investigators. For similar proposals (which are scored on par with each other), the review workgroup leadership will encourage investigators to collaborate on the topic. If collaboration is not feasible, preference will be given to the investigator who first  submitted the idea to the VIRUS ancillary study portal. The VIRUS project manager or study coordinator will reach out to the investigators for the list of data variables requested for the ancillary study.
 

Approval Process

The feedback on proposals will be shared with the investigators. The proposals that are approved, will have to follow the SCCM Discovery publications policies, that will be shared upon proposal approval. The Discovery VIRUS Publication Review Workgroup will make it a priority for rapid review of proposals based on the  timeline given below.

Information for investigators

  1. Any conflict of interest with the ancillary study proposal will be disclosed by the reviewers and the investigators.
  2. The ancillary study proposals have been kept blinded from the VIRUS core investigator group. The first batch of ancillary proposals will be published once the review period closes and notifications are sent to the investigators.
  3. SCCM, including the VIRUS core investigators group, has the first right upon publication of the dataset for research hypothesis outlined for the VIRUS Study.
  4. Study participants can serve on the writing group with the VIRUS core investigators team, if their ancillary study ideas overlap or align with the VIRUS overall project aims.
  5. Collaboration (national & international) on ancillary proposal submissions are encouraged.
  6. Ancillary proposal approval and data sharing will also depend of data quality and completion of investigator’s own site data for the VIRUS study.
 

Timeline

  Ancillary study proposal portal open Ancillary study proposal portal closed Review period Notification
First round of reviews April 15, 2020 May 30, 2020 June 1- June 30, 2020 By July 15, 2020
Second round of reviews July 15, 2020 September 30, 2020 Oct 1 – Oct 30, 2020 By Nov 15, 2020
Third round of reviews December 1, 2020 February 15, 2021 March 1 – March 30, 2021 By April 15, 2021

VIRUS in the News

Press releases and news articles highlighting VIRUS activities.

Learn More

VIRUS Publications

Outcomes and published works from VIRUS.
 

Learn More